Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation?

Nature Clinical Practice Nephrology volume 1, pages 74–75 (2005)Cite this article

boxed-textWatson CJ et al. (2005) Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation—efficacy and safety at five years. Am J Transplant 5: 1347–1353

Clinicians should consider alemtuzumab a safe and effective agent for induction therapy in renal transplantation

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Knechtle SJ et al. (2003) Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 3: 722–730

    Article  CAS  Google Scholar 

  2. Knechtle SJ et al. (2004) Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 136: 754–760

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloe Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Ray D Owen Professor of Transplantation and Director of Liver Transplantation at the University of Wisconsin, Madison, WI, USA

    Stuart J Knechtle

Authors
  1. Stuart J Knechtle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart J Knechtle.

Ethics declarations

Competing interests

The author has received grant support from Berlex Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knechtle, S. How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation?. Nat Rev Nephrol 1, 74–75 (2005). https://doi.org/10.1038/ncpneph0052

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0052

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing